The prevalence of KRAS and BRAF mutation in colorectal cancer patients in Bali

Ayu Dewi Ni Nyoman; Ni Made Pramita Widya Suksmarini; Anak Agung Ngurah Satya Pranata; Andreliano Yosua Rompis; I Wayan Juli Sumadi

doi:10.22146/ijbiotech.67506

The prevalence of KRAS and BRAF mutation in colorectal cancer patients in Bali

https://doi.org/10.22146/ijbiotech.67506

Ayu Dewi Ni Nyoman^(1*), Ni Made Pramita Widya Suksmarini⁽²⁾, Anak Agung Ngurah Satya Pranata⁽³⁾, Andreliano Yosua Rompis⁽⁴⁾, I Wayan Juli Sumadi⁽⁵⁾

(1) Department of Biochemistry, Faculty of Medicine, Udayana University, Jl. PB Sudirman, Denpasar 80232, Indonesia
(2) Faculty of Medicine, Udayana University, Jl. PB Sudirman, Denpasar, 80232 Indonesia
(3) Faculty of Medicine, Udayana University, Jl. PB Sudirman, Denpasar, 80232 Indonesia
(4) Faculty of Medicine, Udayana University, Jl. PB Sudirman, Denpasar, 80232 Indonesia
(5) Department of Pathology, Faculty of Medicine, Udayana University, Jl. PB Sudirman, Denpasar 80232, Indonesia
(*) Corresponding Author

Abstract

Mutations in the KRAS (Kirsten rat sarcoma viral oncogene homolog gene) and BRAF (v‐Raf murine sarcoma viral oncogene homolog B1) gene play a significant role in primary resistance to colorectal cancer therapy. Around 85‐90% of KRAS mutations in colorectal cancer occur in exon 2 (codon 12 and 13), whereas approximately 96% of BRAF mutations occur in exon 15 codon 600 (V600E). This study aimed to determine the prevalence and mutation characteristics of the KRAS and BRAF genes in colorectal cancer patients in Bali. The DNA was isolated from 44 formalin‐fixed paraffin‐embedded colorectal cancer samples which were stored in the Department of Pathology, Sanglah General Hospital in 2017. Detection of mutation was carried out by polymerase chain reaction (PCR) and direct sequencing. Out of 44 samples, only 27 were successfully amplified and sequenced. Our findings showed six samples (22.2%) with mutated KRAS at codons 12 and 13 (including two samples with G12D, one sample with G12V, and three samples with G13D). Interestingly, we found three samples (11.1%) of BRAF mutation, including two samples with V600E mutation and one with V600L mutation. Taken together, our results showed that KRAS and BRAF mutations were identified and occurred exclusively. Further studies are essential to identify the correlation of these mutations with colorectal cancer prognosis and response to chemotherapy

Keywords

BRAF; colorectal cancer; gene mutation; KRAS

Full Text:

PDF

References

American Institute of Cancer Research. 2018. Diet, nutrition, physical activity and colorectal cancer. Contin. Updat. Proj. p. 42–44. URL http://www.aicr.org/continuous-update-project/r eports/breast-cancer-report-2017.pdf. 246

Arrington AK, Heinrich EL, Lee W, Duldulao M, Patel S, Sanchez J, Garcia-Aguilar J, Kim J. 2012. Prognostic and predictive roles of KRAS mutation in colorectal cancer. Int. J. Mol. Sci. 13(10):12153–12168. doi:10.3390/ijms131012153.

Globocan- The Global Cancer Observatory. 2019. Colorectal cancer Source: Globocan 2018. Globocan 2018 876:1–2.

Hernández-Sandoval JA, Gutiérrez-Angulo M, MagañaTorres MT, Alvizo-Rodríguez CR, RamírezPlascencia HHF, Flores-López BA, Valenzuela-Pérez JA, Peregrina-Sandoval J, Moreno-Ortiz JM, Domínguez-Valentín M, Ayala-Madrigal MDLL. 2020. Prevalence of the BRAF p.v600e variant in patients with colorectal cancer from Mexico and its estimated frequency in Latin American and Caribbean populations. J. Investig. Med. 68(5):985–991. doi:10.1136/jim-2020-001301.

Imamura Y, Lochhead P, Yamauchi M, Kuchiba A, Qian ZR, Liao X, Nishihara R, Jung S, Wu K, Nosho K, Wang YE, Peng S, Bass AJ, Haigis KM, Meyerhardt JA, Chan AT, Fuchs CS, Ogino S. 2014. Analyses of clinicopathological, molecular, and prognostic associations of KRAS codon 61 and codon 146 mutations in colorectal cancer: Cohort study and literature review. Mol. Cancer 13(1):1–15. doi:10.1186/1476- 4598-13-135.

Indrayani LPI, Sriwidyani NP. 2017. K-RAS mutation profile in colorectal carcinoma patients in Sanglah Hospital Denpasar, Bali-Indonesia. Bali Med. J. 6(3):40. doi:10.15562/bmj.v6i3.717.

Jones RP, Sutton PA, Evans JP, Clifford R, McAvoy A, Lewis J, Rousseau A, Mountford R, McWhirter D, Malik HZ. 2017. Specific mutations in KRAS codon 12 are associated with worse overall survival in patients with advanced and recurrent colorectal cancer. Br. J. Cancer 116(7):923–929. doi:10.1038/bjc.2017.37.

Kopetz S, Desai J, Chan E, Hecht JR, O’Dwyer PJ, Maru D, Morris V, Janku F, Dasari A, Chung W, Issa JPJ, Gibbs P, James B, Powis G, Nolop KB, Bhattacharya S, Saltz L. 2015. Phase II pilot study of vemurafenib in patients with metastatic BRAF-mutated colorectal cancer. J. Clin. Oncol. 33(34):4032–4038. doi:10.1200/JCO.2015.63.2497.

Kuipers EJ, Grady WM, Lieberman D, Seufferlein T, Sung JJ, Boelens PG, Van De Velde CJ, Watanabe T. 2015. Colorectal cancer. Nat. Rev. Dis. Prim. 1(February 2016):1–25. doi:10.1038/nrdp.2015.65.

Li W, Liu Y, Cai S, Yang C, Lin Z, Zhou L, Liu L, Cheng X, Zeng W. 2019. Not all mutations of KRAS predict poor prognosis in patients with colorectal cancer. Int. J. Clin. Exp. Pathol. 12(3):957–967.

Mao C, Zhou J, Yang Z, Huang Y, Wu X, Shen H, Tang J, Chen Q. 2012. KRAS, BRAF and PIK3CA mutations and the loss of PTEN expression in Chinese patients with colorectal cancer. PLoS One 7(5):1–7. doi:10.1371/journal.pone.0036653.

Mastutik G, Rahniayu A, Rahaju A, Kurniasari N, I’tishom R. 2016. Status mutasi gen kras kodon 12 dan 13 di adenocarcinoma kolorektal [The mutation status of kras gene codon 12 and 13 in colorectal adenocarcinoma]. Indones. J. Clin. Pathol. Med. Lab. 23(1):12– 17. doi:10.24293/ijcpml.v23i1.1177.

Ni Nyoman A, I Wayan J, Sun H. 2020. Molecular Profile of Colorectal Cancer Patients in Bali Based on Methylation of O6-Methylguanine DNA Methyltransferase Promoter Region and Mutation of BRAF and Kirsten RAt Sarcoma Viral Oncogene Homolog Gene. J. Med. Sci. 40(6):257–264. doi:10.4103/jmedsci.jmedsci_205_19.

Phipps AI, Buchanan DD, Makar KW, Win AK, Baron JA, Lindor NM, Potter JD, Newcomb PA. 2013. KRAS-mutation status in relation to colorectal cancer survival: The joint impact of correlated tumour markers. Br. J. Cancer 108(8):1757–1764. doi:10.1038/bjc.2013.118.

Phua LC, Ng HW, Yeo AHL, Chen E, Lo MSM, Cheah PY, Chan ECY, Koh PK, Ho HK. 2015. Prevalence of KRAS, BRAF, PI3K and EGFR mutations among Asian patients with metastatic colorectal cancer. Oncol. Lett. 10(4):2519–2526. doi:10.3892/ol.2015.3560.

Seligmann JF, Fisher D, Smith CG, Richman SD, Elliott F, Brown S, Adams R, Maughan T, Quirke P, Cheadle J, Seymour M, Middleton G. 2017. Investigating the poor outcomes of BRAF-mutant advanced colorectal cancer: Analysis from 2530 patients in randomised clinical trials. Ann. Oncol. 28(3):562–568. doi:10.1093/annonc/mdw645.

Shimada Y, Tajima Y, Nagahashi M, Ichikawa H, Oyanagi H, Okuda S, Takabe K, Wakai T. 2018. Clinical significance of BRAF non-V600E mutations in colorectal cancer: a retrospective study of two institutions. J. Surg. Res. 232:72–81. doi:10.1016/j.jss.2018.06.020.

Siraj AK, Bu R, Prabhakaran S, Bavi P, Beg S, Al Hazmi M, Al-Rasheed M, Alobaisi K, Al-Dayel F, AlManea H, Al-Sanea N, Uddin S, Al-Kuraya KS. 2014. A very low incidence of BRAF mutations in Middle Eastern colorectal carcinoma. Mol. Cancer 13(1):1–9. doi:10.1186/1476-4598-13-168.

Solassol J, Ramos J, Crapez E, Saifi M, Mangé A, Vianès E, Lamy PJ, Costes V, Maudelonde T. 2011. KRAS mutation detection in paired frozen and formalin-fixed paraffin-embedded (FFPE) colorectal cancer tissues. Int. J. Mol. Sci. 12(5):3191–3204. doi:10.3390/ijms12053191.

Taniguchi H, Uehara K, Nakayama G, Nakayama H, Aiba T, Hattori N, Kataoka M, Nakano Y, Kawase Y, Okochi O, Matsuoka H, Utsunomiya S, Sakamoto E, Mori Y, Umeda S, Shikano T, Komori K, Tajika M, Kadowaki S, Muro K, Yatabe Y. 2020. Tumor Location Is Associated With the Prevalence of Braf And Pik3ca Mutations in Patients with Wild-Type Ras Colorectal Cancer: A Prospective Multi-Center Cohort Study in Japan. Transl. Oncol. 13(7):100786. doi:10.1016/j.tranon.2020.100786.

Wang J, Shen J, Huang C, Cao M, Shen L. 2019. Clinicopathological significance of BRAFV600E mutation in colorectal cancer: An updated meta-analysis. J. Cancer 10(10):2332–2341. doi:10.7150/jca.30789.

Warsinggih, Liliyanto, Marhamah, Kusuma MI, Uwuratuw JA, Syarifuddin E, Faruk M. 2020. Relationship between BRAF V600E and KRAS mutations in stool for identifying colorectal cancer: A crosssectional study. Ann. Med. Surg. 60(August):121– 125. doi:10.1016/j.amsu.2020.10.027.

World Health Organization. 2019. Indonesia Source GLOBOCAN 2018. Int. Agency Res. Cancer 256:1– 2.

Yoon HH, Shi Q, Alberts SR, Goldberg RM, Thibodeau SN, Sargent DJ, Sinicrope FA. 2015. Racial Differences in BRAF/KRAS Mutation Rates and Survival in Stage III Colon Cancer Patients. J. Natl. Cancer Inst. 107(10):1–10. doi:10.1093/jnci/djv186.

Zhao B, Wang L, Qiu H, Zhang M, Sun L, Peng P, Yu Q, Yuan X. 2017. Mechanisms of resistance to anti-EGFR therapy in colorectal cancer. Oncotarget 8(3):3980–4000. doi:10.18632/oncotarget.14012.

DOI: https://doi.org/10.22146/ijbiotech.67506